UroGen posts $50.4 million ZUSDURI revenue, cites patent allowance and pipeline progress
UroGen reported second-quarter ZUSDURI sales up 73% from the prior quarter and outlined next steps for UGN-103, UGN-104 and UGN-501, alongside a Teva patent settlement on JELMYTO.
SEC filing